Annexin Pharmaceuticals AB (ANNX) Stock Statistics & Valuation Metrics

Annexin Pharmaceuticals AB has a market cap or net worth of kr106.80M. The enterprise value is kr68.70.

Annexin Pharmaceuticals AB has 8,718,182 shares outstanding. The number of shares has decreased by -2.65% in one year.

Annexin Pharmaceuticals AB’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -145.65%.

The current PE Ratio of Annexin Pharmaceuticals AB is ―. Annexin Pharmaceuticals AB’s PEG ratio is -0.00071.

In the last 12 months, Annexin Pharmaceuticals AB had revenue of 0.00 and earned -36.89M in profits. Earnings per share was -5.58.

In the last 12 months, operating cash flow was -29.07M and capital expenditures -129.00K, giving a free cash flow of -29.20M billion.

Annexin Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―

Annexin Pharmaceuticals AB upcoming earnings date is Feb 5, 2025, Before Open (Confirmed).

Annexin Pharmaceuticals AB as a current ratio of 5.47, with Debt / Equity ratio of 0.00%

In the past 12 months, Annexin Pharmaceuticals AB has paid 0.00 in taxes.

Annexin Pharmaceuticals AB EV to EBITDA ratio is -2.81, with an EV/FCF ratio of -2.80.

Annexin Pharmaceuticals AB has kr17.07M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr17.07M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Annexin Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―